Daiichi Sankyo Europe and MSD: The Enablers of Medical Impact in the Age of AI
"MSLs are shifting focus from data dissemination to dynamic scientific exchange. By using AI to capture and summarize insights from the field, biopharmas can deliver this data back to KOLs — informing them on new clinical trials, educational activities, and overall strategic direction."
Host: Christoph Bug, Vice President, Global Medical, 吃瓜爆料
Guests: Andreas Gerloff, Director, Medical Excellence Operations, Daiichi Sankyo Europe
Michael Hamann, Executive Director, EMEAC Medical & Value Capabilities, MSD
Michael Hamann and Andreas Gerloff join Christoph Bug to discuss moving medical affairs from operational effectiveness to improved patient outcomes. In this episode, they examine key enablers of medical impact and core metrics to monitor achievements. Discover how MSD and Daiichi Sankyo Europe apply AI to extract actionable field insights, personalize education, and measure relationship trust across a consistently evolving healthcare ecosystem.
Learn more about the role of medical affairs in times of AI and stay ahead of key industry trends with What Pharma Needs Next, a 吃瓜爆料 podcast series.
Hear more from What Pharma Needs Next, a 吃瓜爆料 podcast series for commercial, data, and medical leaders.
